EQUETRO (carbamazepine) by Bausch Health is cytochrome p450 3a4 inducers [moa]. First approved in 2004.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
EQUETRO is an extended-release oral capsule formulation of carbamazepine, a mood stabilizer approved in 2004 for bipolar disorder maintenance treatment. It works as a cytochrome P450 3A4 inducer, modulating neuronal activity to stabilize mood and prevent relapse. The extended-release formulation provides improved dosing convenience compared to immediate-release alternatives.
This product is in late-stage lifecycle with minimal Part D spending, indicating a mature market with limited growth opportunities for commercial team expansion.
Cytochrome P450 3A4 Inducers
Mood Stabilizer
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
Worked on EQUETRO at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEQUETRO currently has zero linked job openings and is approaching loss-of-exclusivity, making it a challenging career assignment for growth-oriented professionals. Roles on this product focus on defending market share and managing transition to generic competition rather than expansion and innovation.